Drugs / Aviptadil
Aviptadil
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT04536350 | May 2021 → Jun 2023 | COVID-19, acute respiratory distress syndrome | Prof. Dr. Jörg Leuppi | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04844580 | Mar 2021 → Jun 2022 | COVID-19 | Centurion Pharma | Completed | Met primary |
| Phase 2 | NCT04488081 | Jul 2020 → Jul 2028 expected | COVID-19 | QuantumLeap Healthcare Collaborative | Active not recruiting | Missed primary |
| Phase 2/32 trials · 1 missed | ||||||
| Phase 2/3 | NCT04360096 | Feb → Dec 2021 | COVID-19, acute lung injury, acute respiratory distress syndrome | APR Applied Pharma Research s.a. | Terminated | No outcome recorded Stop: Business |
| Phase 2/3 | NCT04311697 | May 2020 → Feb 2021 | COVID-19, acute lung injury, acute respiratory distress syndrome | APR Applied Pharma Research s.a. | Completed | Missed primary |
| Phase 33 trials · 1 missed | ||||||
| Phase 3 | NCT05137795 | Dec 2021 → Jun 2022 | COVID-19, acute lung injury, acute respiratory distress syndrome | APR Applied Pharma Research s.a. | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT06729606 | Apr 2021 → Aug 2022 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Missed primary |
| Phase 3 | NCT04843761 | Apr 2021 → Aug 2022 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT04453839 | — | respiratory failure | APR Applied Pharma Research s.a. | No longer available | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-08-04 | Mannkind Corporation | MannKind Partners With NRx Pharmaceuticals To Explore A Dry Powder Formulation Of ZYESAMI™ (aviptadil) Based On The Technosphere® Platform mannkindcorp.com ↗ |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Aviptadil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04536350 ↗ |
| Known as | aviptadil acetate | “Patients with severe COVID-19 by FDA definition who have not developed respiratory failure be treated with nebulized ZYESAMI™ (aviptadil acetate, a synthetic version of...” NCT04360096 ↗2“nebulized ZYESAMI™ (aviptadil acetate, a synthetic version of Vasoactive Intestinal Polypeptide (VIP)) 100 μg 3x daily plus Standard of Care” NCT05137795 ↗ “ZYESAMI (aviptadil acetate)” NCT04453839 ↗ |
| Known as | Vasoactive Intestinal Peptide | “Vasoactive Intestinal Peptide (Aviptadil)” PMID 36044317 ↗ Aug 2022 |
| Known as | VIP | “Aviptadil (synthetic VIP)” PMID 36044317 ↗ Aug 2022 |
| Known as | ZYESAMI | “Patients with severe COVID-19 by FDA definition who have not developed respiratory failure be treated with nebulized ZYESAMI™ (aviptadil acetate, a synthetic version of...” NCT04360096 ↗2“nebulized ZYESAMI™ (aviptadil acetate, a synthetic version of Vasoactive Intestinal Polypeptide (VIP)) 100 μg 3x daily plus Standard of Care” NCT05137795 ↗ “ZYESAMI (aviptadil) is a synthetic form of Vasoactive Intestinal Polypeptide (VIP), a ubiquitous, naturally synthesized human peptide” NCT04453839 ↗ |
| Action | Inhibit | “inhibits IL-6 and TNFa production” NCT04536350 ↗ |
| Modality | Peptide | “synthetic form of Human Vasoactive Intestinal Polypeptide (VIP)” NCT04311697 ↗ |
| Route | Intravenous | “Aviptadil administered by intravenous infusion” NCT04311697 ↗ |
| Target | IL6 | “inhibits IL6 and TNFα production” NCT05137795 ↗ |
| Target | TNF | “inhibits IL6 and TNFα production” NCT05137795 ↗ |